Ovarian Cancer Coverage from Every Angle

Ursula A. Matulonis, MD, on Current Therapies vs Novel Antibody-Drug Conjugates

Posted: Tuesday, July 30, 2019

Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, compares currently available therapies for patients with ovarian cancer with novel antibody-drug conjugates such as XMT-1536 or mirvetuximab soravtansine.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.